DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLE, PROCESS FOR PRODUCING THE SAME AND PREPARATION CONTAINING THE MICROPARTICLE
    3.
    发明申请
    DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLE, PROCESS FOR PRODUCING THE SAME AND PREPARATION CONTAINING THE MICROPARTICLE 失效
    包含持续释放微生物的药物,其生产方法和含有微生物的制剂

    公开(公告)号:US20100322902A1

    公开(公告)日:2010-12-23

    申请号:US12837810

    申请日:2010-09-02

    Abstract: Sustained release microparticles suitable for various types of drugs, or drug-containing sustained release microparticles capable of sustained release of drugs over a period of three days or more and capable of inhibiting initial burst release; a process for producing the same; and preparations containing the microparticles are disclosed. The drug-containing sustained release microparticles comprise a drug other than human growth hormone and a porous apatite derivative, and optionally include a water-soluble bivalent metal compound. The drug-containing sustained release microparticles can be produced by dispersing under agitation microparticles of a porous apatite derivative in an aqueous solution containing a drug so that the aqueous solution infiltrates into the porous apatite derivative; optionally adding an aqueous solution containing a water-soluble bivalent metal compound that may infiltrate into the porous apatite derivative; further adding additives such as a stabilizer to the mixture; and effecting lyophilization or vacuum drying.

    Abstract translation: 适用于各种类型药物的持续释放微粒,或能够在三天或更长时间内持续释放药物并且能够抑制初始爆发释放的药物持续释放微粒; 其制造方法; 并且公开了含有微粒的制剂。 含药物的缓释微粒包含除人生长激素以外的药物和多孔磷灰石衍生物,任选地包含水溶性二价金属化合物。 含药缓释微粒可以通过将多孔磷灰石衍生物的微粒分散在含有药物的水溶液中分散而制成,使得水溶液渗透到多孔磷灰石衍生物中; 任选地加入含有可渗透到多孔磷灰石衍生物中的水溶性二价金属化合物的水溶液; 进一步向混合物中加入稳定剂等添加剂; 并进行冻干或真空干燥。

    Biological low-molecular-weight derivatives
    5.
    发明授权
    Biological low-molecular-weight derivatives 失效
    生物低分子量衍生物

    公开(公告)号:US07741454B2

    公开(公告)日:2010-06-22

    申请号:US10527694

    申请日:2003-09-11

    CPC classification number: C07D207/02 C07D207/46

    Abstract: The crosslinking agents and condensing agents that have been employed in biological adhesives and in treating medical devices such as cardiac valves are non-natural compounds synthesized artificially. Thus, they are not metabolized in vivo and exhibit toxicity to living bodies. These compounds are thus used only in a restricted amount and for limited purposes in the clinical sites. The present invention provides a biological low-molecular-weight derivative obtained by modifying carboxyl groups of a biological low-molecular-weight compound with N-hydroxysuccinimide, N-hydroxysulfosuccinimide, or a derivative thereof and a crosslinked high-molecular-weight product obtained by crosslinking various high-molecular-weight compounds with this derivative.

    Abstract translation: 已经用于生物粘合剂和治疗医疗装置如心脏瓣膜的交联剂和缩合剂是人工合成的非天然化合物。 因此,它们不会在体内代谢并对活体表现出毒性。 因此,这些化合物仅在临床部位中仅限于有限的目的和用途。 本发明提供一种通过用N-羟基琥珀酰亚胺,N-羟基磺基琥珀酰亚胺或其衍生物修饰生物低分子量化合物的羧基得到的生物学低分子量衍生物和通过以下方法得到的交联的高分子量产物: 用该衍生物交联各种高分子量化合物。

    Biodegradable and pressure-sensitive material for medical use
    9.
    发明申请
    Biodegradable and pressure-sensitive material for medical use 审中-公开
    用于医疗用途的可生物降解和压敏材料

    公开(公告)号:US20060239958A1

    公开(公告)日:2006-10-26

    申请号:US10543156

    申请日:2004-02-05

    CPC classification number: A61L24/043 A61L24/0042 A61L2430/36

    Abstract: Disclosed is a two-component, bio-degradable/absorbable adhesive medical material, which has a bonding component comprising a biodegradable polymer, and a hardening component comprising a low-molecular-weight derivative prepared by modifying a carboxyl group in a di- or tri-carboxylic acid of the citric acid cycle, with an electron-attracting group (one or a combination of two or more selected from the group consisting of a succinimidyl group, a sulfosuccinimidyl group, a maleimidyl group, a phthalimidyl group, an imidazolyl group, a nitrophenyl group and a tresyl group, and derivatives thereof). The present invention is intended to meet the need for developing a biological tissue adhesive having strong bonding force and low biological toxicity, in the situation where a conventional hemostatic material, blood-vessel embolizing material, sealant or aneurysm closing material has been liable to peel off from its applied site and has not been able to achieve sufficient hemostatic effect or sealing/closing strength in occluding a blood vessel, stopping bleeding, sealing air-leak or closing an aneurysm.

    Abstract translation: 公开了一种双组分生物可降解/可吸收的粘合剂医疗材料,其具有包含可生物降解的聚合物的粘合组分和包含通过改性二 - 或三(C)中的羧基制备的低分子量衍生物的硬化组分 - 具有吸电子基团(一种或两种或更多种选自琥珀酰亚胺基,磺基琥珀酰亚胺基,马来酰亚胺基,苯二酰亚胺基,咪唑基,咪唑基, 硝基苯基和甲酚基,及其衍生物)。 本发明旨在满足在常规止血材料,血管栓塞材料,密封剂或动脉瘤闭合材料易于剥离的情况下开发具有强结合力和低生物毒性的生物组织粘合剂的需要 从其应用场所,并且在闭塞血管,停止出血,密封空气泄漏或闭合动脉瘤方面未能达到充分的止血效果或密封/闭合强度。

    Scaffold material for regeneration of hard tissue/soft tissue interface
    10.
    发明申请
    Scaffold material for regeneration of hard tissue/soft tissue interface 失效
    支架材料用于再生硬组织/软组织界面

    公开(公告)号:US20060165663A1

    公开(公告)日:2006-07-27

    申请号:US10516818

    申请日:2003-05-02

    CPC classification number: A61L27/3839 A61L27/46 C08L5/00

    Abstract: This invention relates to a scaffold consisting of a biodegradable polymeric material with a composition gradient of calcium phosphate that is capable of effectively regenerating the hard/soft tissue interface and an implant for hard/soft tissue filling with the utilization of such scaffold.

    Abstract translation: 本发明涉及由能够有效地再生硬/软组织界面的具有磷酸钙组成梯度的可生物降解的聚合物材料和用于硬/软组织填充以利用这种支架的植入物构成的支架。

Patent Agency Ranking